AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
4
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
5
Silverfort acquires Rezonate for several tens of millions to expand cloud security reach
More news

Drugs

20 stories about Drugs
מטה אלי לילי ב אינדיאנפוליס

1,000% stock increase: The story behind Eli Lilly’s pharmaceutical dominance

14.08.24|Viki Auslender
Beating second-quarter forecasts mainly due to its weight loss and diabetes drugs, Eli Lilly, the company aspiring to be worth a trillion dollars, has invested heavily in innovative developments, becoming the pharmaceutical manufacturer with the highest market value in the world.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
קור שולץ מנכ"ל טבע 9.11.19

The U.S. Opioid Abuse Lawsuits Are Political, Says Teva CEO

19.02.20|Sophie Shulman
Teva’s stock fluctuation is not the result of wrongdoing regarding the U.S. opioid abuse epidemic, but rather something born of the creativity of lawyers, Kåre Schultz said Wednesday at the company’s annual press conference in Tel Aviv
לקוחה מתנסה ב מחשב ש מעניק אינפורמציה על תרופות ללא מרשם רפואי

Over-the-Counter Drug Prices in Israel are Much Higher Than Overseas

17.02.20|Orna Yefet
The Israeli Ministries of Health and Economy summoned OTC drug manufacturers and distributors for meetings after a study found prices are 37% higher on average in Israel
מוסף תרופה תרופות בית מרקחת

Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns

16.02.20|Lilach Baumer
On Thursday, the manufacturer of Belviq weight loss drug, Eisai, announced it was withdrawing the drug from the U.S. market after a five-year trial found it increased risk of cancer by 0.6%
קור שולץ מנכ"ל טבע 9.11.19

Teva’s Small Print Gives Rise to Optimism

13.02.20|Sophie Shulman
The improvement CEO Kåre Shultz promised is not immediately evident in the drugmaker’s forecast for 2020, but a closer look shows Teva’s new brand drugs are starting to live up to their promise
קור שולץ מנכ"ל טבע 9.11.19

Teva Fights Muddy Reputation With Positive Report

23.01.20|Sophie Shulman
Calcalist obtained a report commissioned by the Israeli drugmaker that details its economic contribution to the countries in which it operates
זריקה חיסון רופא מוסף

Fat Melting Startup Raziel Therapeutics Raises $22 Million

19.12.19|Adi Pick
The company's drug is injected into subcutaneous fat where it causes immediate fat cell death at the injection site, resulting in a reduction of fat tissue
מטה חברת טבע תרופות

Teva in Talks With U.S. DoJ to End Price-Fixing Probe, Report Says

26.11.19|CTech
The Israeli drugmaker, along with several other companies investigated in the matter, have been holding talks on the subject for the past six months, Bloomberg reported
אתר טבע כפר סבא

Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing

17.11.19|Navit Zomer
The Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
מוסף תרופה תרופות בית מרקחת

RedHill Receives FDA Approval for H. Pylori Gastric Drug

05.11.19|Tzally Greenberg
H. pylori is a type of drug-resistant gastric bacteria linked with increased risks of developing ulcers and stomach cancer
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
מטה חברת טבע תרופות

Teva Part of $50 Billion Opioid Settlement Deal, Report Says

17.10.19|Hezi Sternlicht
Teva, a second drugmaker, and the three largest drug distributors in the U.S. have agreed with multiple states on a settlement framework ahead of Monday’s trial, the New York Times reported Thursday
אתר טבע כפר סבא

Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says

16.10.19|Hezi Sternlicht
The Israeli drugmaker and several other drug distributors are set to face around 2,500 lawsuits related to the U.S. opioid abuse epidemic in just a week at a Cleveland, Ohio federal court
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אתר טבע כפר סבא

Teva Faces New Opioid-Related Lawsuit in West Virginia

25.08.19|Hezi Sternlicht
The lawsuit seems to be unrelated to the trial set to start against Teva and other opioid manufacturers in October in Ohio federal court
יוסי משי טלגראס

Telegrass' Marijuana Operation: Method, Testimonies, and Question Marks

10.07.19|Amir Kurz
On March 12, Israel Police arrested 42 people suspected of holding top management positions in Israeli drug distribution network Telegrass, which operated via encrypted instant messaging app Telegram
מטה חברת טבע תרופות

Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit

27.05.19|Hezi Sternlicht
Teva is one of several opioid manufacturers being sued in the U.S. by different states and private entities for its alleged role in the nation's opioid addiction crisis
מטה חברת טבע תרופות

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer Ganon
A 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
More Articles